Comparison · NCT04333732-4a9bb3c1
M-M-R II ® vs Placebo: Number of Participants With Symptomatic COVID-19 at 150 Days
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. M-M-R II ® vs Placebo: Number of Participants With Symptomatic COVID-19 at 150 Days. Trial comparisons, record NCT04333732-4a9bb3c1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04333732-4a9bb3c1
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.041 | 0.0323 | 0.0519 | wilson | |
| Risk in group 2 | 0.0415 | 0.0326 | 0.0526 | wilson | |
| Risk difference, group 1 minus group 2 | -0.000441 | -0.0146 | 0.0136 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.989 | 0.706 | 1.39 | log | |
| Odds ratio, group 1 over group 2 | 0.989 | 0.695 | 1.41 | log | |
| Number needed to treat, for one fewer participant with the outcome on M-M-R II ® than on Placebo | 2,270 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | M-M-R II ® | Education and surveillance plus M-M-R II ®~MR or M-M-R II ® vaccine: Education and surveillance plus MR or M-M-R II ® vaccine | 65 | 1,585 | OG000 |
| Group 2 | Placebo | Education and surveillance plus placebo~Placebo: Placebo injection | 64 | 1,544 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Symptomatic COVID-19 at 150 Days
- Description
Incidence of symptomatic (i.e. any of the following: cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell, nausea, vomiting, or diarrhea), laboratory test-confirmed COVID-19 in the intervention and control groups in adults with repeated exposures to SARS-CoV-2 by day 150 after receiving trial intervention.
- Time frame
- 150 days after receiving trial intervention
- Population
Source ClinicalTrials.gov
Trial
- Title
- CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
- NCT number
- NCT04333732
- Phases
- PHASE3
- Conditions
- COVID 19
- Interventions
- MR or M-M-R II ® vaccine, Placebo
- Lead sponsor
- Washington University School of Medicine
- Results first posted
- 2024-03-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04333732?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04333732-4a9bb3c1